Tesamorelin is a synthetic peptide analog of growth hormone–releasing hormone (GHRH) used clinically to treat HIV-associated lipodystrophy (excess abdominal fat).
- FDA-approved (brand name: Egrifta SV)
- Developed by Theratechnologies
- Administered via subcutaneous injection
- Designed to stimulate the body’s natural growth hormone (GH) production
👉 In simple terms:
Tesamorelin tells your brain (pituitary) to release more of your own growth hormone, rather than supplying it externally.
Features
1. GHRH Analog Mechanism (Core Feature)
- Mimics the body’s natural growth hormone–releasing hormone
- Binds to pituitary receptors → triggers pulsatile GH release
- Leads to increased IGF-1 (insulin-like growth factor 1) production
👉 This preserves a natural hormone rhythm, unlike synthetic GH injections.
2. Targeted Visceral Fat Reduction
- Specifically reduces visceral (deep abdominal) fat
- Has minimal effect on subcutaneous fat
- Works via GH-driven lipolysis (fat breakdown)
👉 This is its main FDA-approved use.
3. Metabolic & Body Composition Effects
- ↑ Fat metabolism (especially abdominal fat)
- ↑ Lean body mass preservation
- ↑ IGF-1 levels (~significant increase)
- ↓ Triglycerides and liver fat (observed in studies)
4. Enhanced Stability vs Natural GHRH
- Contains a trans-3-hexenoic acid modification
- More resistant to enzymatic breakdown (e.g., DPP-4)
- Provides greater potency and duration than native GHRH
5. Clinically Validated Peptide
- Backed by Phase III clinical trials
- One of the few peptides with full FDA approval for a metabolic indication
Reviews
There are no reviews yet.